Progentec is engaged in state of the art diagnostic interventions in therapeutic areas with a high level of unmet need.
Progentec Diagnostics was set up to explore and commercialize state of the art diagnostic interventions in therapeutic areas with a high level of unmet need. The company is collaborating with a number of research institutions and individuals around the world engaged in bringing the latest technological innovations to the field of diagnostics. The commitment to this cause is firmly rooted in our belief that better diagnostics would not only help in better and less costly management of diseases, but also help tremendously in reducing the incidence of diseases through early screening and detection.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 9, 2020 | Series A | $5M | 1 | Plains Venture Partners | — | Detail |
Nov 2, 2018 | Series Unknown | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Plains Venture Partners | Yes | Series A |
NMC Lifesciences | — | Series Unknown |